PUBLICATIONS · 11248153
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Open original source → · Download preserved record
Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.
- Journal
- N Engl J Med
- Publication date
- 2001 Mar 15
- First author
- Slamon DJ
Publication notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- N Engl J Med. 2001 Sep 27;345(13):995-6. doi: 10.1056/NEJM200109273451312.
- note
- Source null
- related pmid
- 11575295
- relationship
- Comment in
- citation
- N Engl J Med. 2001 Sep 27;345(13):996.
- note
- Source null
- related pmid
- 11575296
- relationship
- Comment in
- citation
- N Engl J Med. 2001 Sep 27;345(13):996-7.
- note
- Source null
- related pmid
- 11575297
- relationship
- Comment in
Authors and identifiers
- name
- Slamon DJ
- type
- Author
- name
- Leyland-Jones B
- type
- Author
- name
- Shak S
- type
- Author
- name
- Fuchs H
- type
- Author
- name
- Paton V
- type
- Author
- name
- Bajamonde A
- type
- Author
- name
- Fleming T
- type
- Author
- name
- Eiermann W
- type
- Author
- name
- Wolter J
- type
- Author
- name
- Pegram M
- type
- Author
- name
- Baselga J
- type
- Author
- name
- Norton L
- type
- Author
Complete bibliographic record and source provenance
- authors
- name
- Slamon DJ
- type
- Author
- name
- Leyland-Jones B
- type
- Author
- name
- Shak S
- type
- Author
- name
- Fuchs H
- type
- Author
- name
- Paton V
- type
- Author
- name
- Bajamonde A
- type
- Author
- name
- Fleming T
- type
- Author
- name
- Eiermann W
- type
- Author
- name
- Wolter J
- type
- Author
- name
- Pegram M
- type
- Author
- name
- Baselga J
- type
- Author
- name
- Norton L
- type
- Author
- bibliography ids
- nci-bib-b134846de43f783ce3302e49
- book metadata
- content sha256
- ad295560590e5140cc63cb6766c90c9d19521ee6bc6d5dd212cfc30988c8051a
- document type
- citation
- dois
- 10.1056/NEJM200103153441101
- electronic publication date
- display
- Source null
- precision
- missing
- year
- Source null
- evidence scope
- bibliographic_metadata_only
- id
- pubmed:11248153
- immutable id
- pubmed:11248153@ad295560590e5140cc63cb6766c90c9d19521ee6bc6d5dd212cfc30988c8051a
- journal
- abbreviation
- N Engl J Med
- issn electronic
- Source null
- issn print
- 0028-4793
- issue
- 11
- name
- The New England journal of medicine
- nlm unique id
- 0255562
- pages
- 783-92
- volume
- 344
- languages
- eng
- notices
- absence is not clearance
- true
- has correction metadata
- false
- has expression of concern metadata
- false
- has retraction in link
- false
- pubmed marks article retracted
- false
- pubmed marks retraction notice
- false
- relationships
- citation
- N Engl J Med. 2001 Sep 27;345(13):995-6. doi: 10.1056/NEJM200109273451312.
- note
- Source null
- related pmid
- 11575295
- relationship
- Comment in
- citation
- N Engl J Med. 2001 Sep 27;345(13):996.
- note
- Source null
- related pmid
- 11575296
- relationship
- Comment in
- citation
- N Engl J Med. 2001 Sep 27;345(13):996-7.
- note
- Source null
- related pmid
- 11575297
- relationship
- Comment in
- outcomes validated
- false
- pmid
- 11248153
- provenance
- batch id
- 30d2cd7affbbb92b6784
- provider
- NCBI PubMed ESummary
- record sha256
- 8c2373886d686b246faa886f79ff2404f92a96bf4a11e90395c4073a3bfba4c4
- response sha256
- ae7ed930f8b43c9e34eeae02f278f33f49c15777b81f742392c120eb64949120
- retrieved at
- 2026-09-09T23:45:39.779418+00:00
- publication date
- display
- 2001 Mar 15
- precision
- day
- year
- 2001
- publication types
- Clinical Trial
- Journal Article
- Multicenter Study
- Randomized Controlled Trial
- Research Support, Non-U.S. Gov't
- record status
- PubMed - indexed for MEDLINE
- schema version
- 1.0
- title
- Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
Preserved source evidence · Not medical advice
Triangle